AbbVie is joining the chase for new obesity drugs, but rather than getting a me-too GLP-1 drug, the pharmaceutical giant is landing rights to a clinical-stage molecule that goes after two novel ...
AbbVie Inc. (NYSE:ABBV) entered the obesity race last week when it in-licensed GUB014295 (also called GUBamy) from Denmark-based Gubra. The candidate is a long-acting amylin analog for the ...
Healthcare & Pharmaceuticalscategory· February 7, 2025 US FDA approves AbbVie-Pfizer's treatment for intra-abdominal infections AbbVie said on Friday that the U.S. Food and Drug Administration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback